180 related articles for article (PubMed ID: 31062122)
1. Magnetic resonance imaging-guided transurethral ultrasound ablation of prostate tissue in patients with localized prostate cancer: single-center evaluation of 6-month treatment safety and functional outcomes of intensified treatment parameters.
Hatiboglu G; Popeneciu V; Bonekamp D; Burtnyk M; Staruch R; Pahernik S; Tosev G; Radtke JP; Motsch J; Schlemmer HP; Hohenfellner M; Nyarangi-Dix JN
World J Urol; 2020 Feb; 38(2):343-350. PubMed ID: 31062122
[TBL] [Abstract][Full Text] [Related]
2. Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Tissue in Patients with Localized Prostate Cancer: A Prospective Phase 1 Clinical Trial.
Chin JL; Billia M; Relle J; Roethke MC; Popeneciu IV; Kuru TH; Hatiboglu G; Mueller-Wolf MB; Motsch J; Romagnoli C; Kassam Z; Harle CC; Hafron J; Nandalur KR; Chronik BA; Burtnyk M; Schlemmer HP; Pahernik S
Eur Urol; 2016 Sep; 70(3):447-55. PubMed ID: 26777228
[TBL] [Abstract][Full Text] [Related]
3. Single center retrospective analysis of fifty-two prostate cancer patients with customized MR-guided transurethral ultrasound ablation (TULSA).
Lumiani A; Samun D; Sroka R; Muschter R
Urol Oncol; 2021 Dec; 39(12):830.e9-830.e16. PubMed ID: 34144892
[TBL] [Abstract][Full Text] [Related]
4. Magnetic resonance imaging-guided transurethral ultrasound ablation for benign prostatic hyperplasia: 12-month clinical outcomes of a phase I study.
Viitala A; Anttinen M; Wright C; Virtanen I; Mäkelä P; Hovinen T; Sainio T; Saunavaara J; Taimen P; Blanco Sequeiros R; Boström PJ
BJU Int; 2022 Feb; 129(2):208-216. PubMed ID: 34161649
[TBL] [Abstract][Full Text] [Related]
5. Relief of Lower Urinary Tract Symptoms After MRI-Guided Transurethral Ultrasound Ablation for Localized Prostate Cancer: Subgroup Analyses in Patients with Concurrent Cancer and Benign Prostatic Hyperplasia.
Elterman D; Li W; Hatiboglu G; Relle J; Zorn KC; Bhojani N; Chin J
J Endourol; 2021 Apr; 35(4):497-505. PubMed ID: 32935575
[No Abstract] [Full Text] [Related]
6. Twelve-month prostate volume reduction after MRI-guided transurethral ultrasound ablation of the prostate.
Bonekamp D; Wolf MB; Roethke MC; Pahernik S; Hadaschik BA; Hatiboglu G; Kuru TH; Popeneciu IV; Chin JL; Billia M; Relle J; Hafron J; Nandalur KR; Staruch RM; Burtnyk M; Hohenfellner M; Schlemmer HP
Eur Radiol; 2019 Jan; 29(1):299-308. PubMed ID: 29943185
[TBL] [Abstract][Full Text] [Related]
7. Magnetic resonance imaging-guided transurethral ultrasound ablation in patients with localised prostate cancer: 3-year outcomes of a prospective Phase I study.
Nair SM; Hatiboglu G; Relle J; Hetou K; Hafron J; Harle C; Kassam Z; Staruch R; Burtnyk M; Bonekamp D; Schlemmer HP; Roethke MC; Mueller-Wolf M; Pahernik S; Chin JL
BJU Int; 2021 May; 127(5):544-552. PubMed ID: 33037765
[TBL] [Abstract][Full Text] [Related]
8. Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Cancer: A Systematic Review.
Dora C; Clarke GM; Frey G; Sella D
J Endourol; 2022 Jun; 36(6):841-854. PubMed ID: 35029127
[No Abstract] [Full Text] [Related]
9. Single-Center Evaluation of Treatment Success Using Two Different Protocols for MRI-Guided Transurethral Ultrasound Ablation of Localized Prostate Cancer.
Hatiboglu G; Popeneciu V; Bonekamp D; Burtnyk M; Staruch R; Distler F; Radtke JP; Motsch J; Schlemmer HP; Pahernik S; Nyarangi-Dix J
Front Oncol; 2021; 11():782546. PubMed ID: 34778095
[TBL] [Abstract][Full Text] [Related]
10. Feasibility of MRI-guided transurethral ultrasound for lesion-targeted ablation of prostate cancer.
Anttinen M; Mäkelä P; Suomi V; Kiviniemi A; Saunavaara J; Sainio T; Horte A; Eklund L; Taimen P; Sequeiros RB; Boström PJ
Scand J Urol; 2019 Oct; 53(5):295-302. PubMed ID: 31556779
[No Abstract] [Full Text] [Related]
11. Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Cancer.
Klotz L; Pavlovich CP; Chin J; Hatiboglu G; Koch M; Penson D; Raman S; Oto A; Fütterer J; Serrallach M; Relle J; Lotan Y; Heidenreich A; Bonekamp D; Haider M; Tirkes T; Arora S; Macura KJ; Costa DN; Persigehl T; Pantuck AJ; Bomers J; Burtnyk M; Staruch R; Eggener S
J Urol; 2021 Mar; 205(3):769-779. PubMed ID: 33021440
[TBL] [Abstract][Full Text] [Related]
12. First experiences using transurethral ultrasound ablation (TULSA) as a promising focal approach to treat localized prostate cancer: a monocentric study.
Peters I; Hensen B; Glandorf J; Gutberlet M; Dohna M; Struckmann S; Kuczyk MA; Wacker F; Hellms S
BMC Urol; 2023 Aug; 23(1):142. PubMed ID: 37644453
[TBL] [Abstract][Full Text] [Related]
13. MRI-guided Focused Ultrasound Ablation for Localized Intermediate-Risk Prostate Cancer: Early Results of a Phase II Trial.
Ghai S; Finelli A; Corr K; Chan R; Jokhu S; Li X; McCluskey S; Konukhova A; Hlasny E; van der Kwast TH; Incze PF; Zlotta AR; Hamilton RJ; Haider MA; Kucharczyk W; Perlis N
Radiology; 2021 Mar; 298(3):695-703. PubMed ID: 33529137
[TBL] [Abstract][Full Text] [Related]
14. Magnetic resonance image guided transurethral ultrasound prostate ablation: a preclinical safety and feasibility study with 28-day followup.
Burtnyk M; Hill T; Cadieux-Pitre H; Welch I
J Urol; 2015 May; 193(5):1669-75. PubMed ID: 25464003
[TBL] [Abstract][Full Text] [Related]
15. Image-guided Irreversible Electroporation of Localized Prostate Cancer: Functional and Oncologic Outcomes.
Collettini F; Enders J; Stephan C; Fischer T; Baur ADJ; Penzkofer T; Busch J; Hamm B; Gebauer B
Radiology; 2019 Jul; 292(1):250-257. PubMed ID: 31161973
[TBL] [Abstract][Full Text] [Related]
16. MR Imaging-Guided Transurethral Ultrasound Ablation of Localized Prostate Cancer: Preliminary Experience from a Single Center in a Prospective, Multi-Center, Single-Arm Clinical Trial.
Sundaram KM; Staruch R; Burtnyk M; Lane JS; Penson DF; Arora SS
J Vasc Interv Radiol; 2020 May; 31(5):740-746.e4. PubMed ID: 32307311
[TBL] [Abstract][Full Text] [Related]
17. MR-Guided Transurethral Ultrasound Ablation (TULSA)-An Emerging Minimally Invasive Treatment Option for Localised Prostate Cancer.
Fung KFK; Cazzato RL; Tricard T; Marini PDE; Bertucci G; Autrusseau PA; Koch G; Weiss J; Garnon J; Lang H; Gangi A
Cardiovasc Intervent Radiol; 2024 Jun; 47(6):689-701. PubMed ID: 38491163
[TBL] [Abstract][Full Text] [Related]
18. Salvage open radical prostatectomy for recurrent prostate cancer following MRI-guided transurethral ultrasound ablation (TULSA) of the prostate: feasibility and efficacy.
Nair SM; Stern N; Dewar M; Siddiqui K; Smith E; Gomez JA; Moussa M; Chin JL
Scand J Urol; 2020 Jun; 54(3):215-219. PubMed ID: 32308085
[No Abstract] [Full Text] [Related]
19. Salvage Magnetic Resonance Imaging-guided Transurethral Ultrasound Ablation for Localized Radiorecurrent Prostate Cancer: 12-Month Functional and Oncological Results.
Anttinen M; Mäkelä P; Viitala A; Nurminen P; Suomi V; Sainio T; Saunavaara J; Taimen P; Sequeiros RB; Boström PJ
Eur Urol Open Sci; 2020 Dec; 22():79-87. PubMed ID: 34337481
[TBL] [Abstract][Full Text] [Related]
20. Urinary Outcomes After Magnetic Resonance Imaging-Guided Whole-Gland Transurethral Ultrasound Ablation for Prostate Cancer: Comparison of Suprapubic Tube to Indwelling Urethral Catheter.
Rabinowitz MJ; Haney NM; Myers AA; Dora CD; Pavlovich CP
J Endourol; 2023 Jan; 37(1):1-7. PubMed ID: 36017622
[No Abstract] [Full Text] [Related]
[Next] [New Search]
